US 12,030,944 B2
Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
Peter Schnorr, Sudbury, MA (US); Akanksha Chhabra, San Francisco, CA (US); Judith A. Shizuru, Palo Alto, CA (US); Irving L. Weissman, Stanford, CA (US); and Kipp Andrew Weiskopf, Sudbury, MA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Feb. 16, 2023, as Appl. No. 18/110,734.
Application 18/110,734 is a continuation of application No. 17/119,548, filed on Dec. 11, 2020, granted, now 11,608,377.
Application 17/119,548 is a continuation of application No. 15/754,757, granted, now 10,894,831, issued on Jan. 19, 2021, previously published as PCT/US2016/049016, filed on Aug. 26, 2016.
Claims priority of provisional application 62/210,279, filed on Aug. 26, 2015.
Prior Publication US 2023/0257464 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 14/525 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2818 (2013.01) [C07K 14/525 (2013.01); C07K 16/2848 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 2319/00 (2013.01)] 22 Claims
 
1. A method of targeting lymphoma cells for immunodepletion, the method comprising:
contacting a population of cells comprising the targeted lymphoma cells and a population of immune cells with (i) an agent that blockades CD47 activity; and (ii) an antibody that agonizes CD137; in a dose effective to increase depletion of the targeted lymphoma cells.